MX2012005340A - Sistemas de expresion regulada. - Google Patents

Sistemas de expresion regulada.

Info

Publication number
MX2012005340A
MX2012005340A MX2012005340A MX2012005340A MX2012005340A MX 2012005340 A MX2012005340 A MX 2012005340A MX 2012005340 A MX2012005340 A MX 2012005340A MX 2012005340 A MX2012005340 A MX 2012005340A MX 2012005340 A MX2012005340 A MX 2012005340A
Authority
MX
Mexico
Prior art keywords
hepato
promoter
inducer agent
specific
operator
Prior art date
Application number
MX2012005340A
Other languages
English (en)
Inventor
Jesus Maria Prieto Valtuena
Gloria Gonzalez Aseguinolaza
Lucia Maria Vanrell Majo
Original Assignee
Proyecto Biomedicina Cima Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto Biomedicina Cima Sl filed Critical Proyecto Biomedicina Cima Sl
Publication of MX2012005340A publication Critical patent/MX2012005340A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se relaciona con métodos y herramientas para la expresión inducible hepatoespecífica de un gen de interés mediante el uso de promotores bidireccionales hepatoespecíficos que se encuentran operativamente acoplados a dicho gen de interés y a un transactivador que es capaz de promover la transcripción en presencia de un determinado gen de interés. La invención se refiere también a construcciones génicas y viriones que permiten la expresión regulada hepatoespecifica así como al uso de los mismos para el tratamiento de enfermedades hepáticas.
MX2012005340A 2009-11-05 2010-11-04 Sistemas de expresion regulada. MX2012005340A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200902122 2009-11-05
PCT/ES2010/070715 WO2011054994A1 (es) 2009-11-05 2010-11-04 Sistemas de expresión regulada

Publications (1)

Publication Number Publication Date
MX2012005340A true MX2012005340A (es) 2012-12-05

Family

ID=43569271

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012005340A MX2012005340A (es) 2009-11-05 2010-11-04 Sistemas de expresion regulada.

Country Status (10)

Country Link
US (1) US20120225933A1 (es)
EP (1) EP2497830A1 (es)
JP (1) JP2014503173A (es)
CN (1) CN102712933A (es)
AU (1) AU2010316996A1 (es)
BR (1) BR112012010755A2 (es)
CA (1) CA2780671A1 (es)
MX (1) MX2012005340A (es)
RU (1) RU2012123145A (es)
WO (1) WO2011054994A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130034599A1 (en) * 2010-01-19 2013-02-07 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities
JP6591956B2 (ja) * 2013-03-15 2019-10-16 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Ｍｐｓ１を治療するための組成物および方法
CN105316352A (zh) * 2014-07-29 2016-02-10 深圳先进技术研究院 一种调节性表达目的基因的载体及其制备方法和应用
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
EP3184548A1 (en) * 2015-12-23 2017-06-28 Miltenyi Biotec GmbH Chimeric antigen receptor with cytokine receptor activating or blocking domain
US11208669B2 (en) 2016-01-12 2021-12-28 University Of Cincinnati Lentivirus packaging system comprising a synthetic positive feedback loop
SG11201912631PA (en) 2017-07-06 2020-01-30 Univ Pennsylvania Aav9-mediated gene therapy for treating mucopolysaccharidosis type i
CN107365785B (zh) * 2017-09-11 2020-02-18 东南大学 一种调控细胞内NF-κB活性的基因表达载体及其调控方法和应用
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
WO2023178067A1 (en) * 2022-03-16 2023-09-21 Rutgers, The State University Of New Jersey Controlled muscle‐specific gene delivery
CN114891829B (zh) * 2022-05-24 2023-09-26 新乡医学院 一种肝特异性游离型表达载体和基因治疗载体及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970154A (en) 1987-10-09 1990-11-13 Baylor College Of Medicine Method for inserting foreign genes into cells using pulsed radiofrequency
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
WO1995013392A1 (en) 1993-11-09 1995-05-18 Medical College Of Ohio Stable cell lines capable of expressing the adeno-associated virus replication gene
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5484720A (en) 1994-09-08 1996-01-16 Genentech, Inc. Methods for calcium phosphate transfection
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
JPH10511264A (ja) 1994-12-06 1998-11-04 ターゲティッド ジェネティックス コーポレイション 高力価組換えａａｖベクターの生成のためのパッケージング細胞株
US5891680A (en) 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
EP0832269A1 (en) 1995-06-07 1998-04-01 Baylor College Of Medicine Nucleic acid transporters for delivery of nucleic acids into a cell
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
US5679559A (en) 1996-07-03 1997-10-21 University Of Utah Research Foundation Cationic polymer and lipoprotein-containing system for gene delivery
AU4645697A (en) 1996-09-11 1998-04-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Aav4 vector and uses thereof
AU5603998A (en) 1996-12-18 1998-07-15 Targeted Genetics Corporation Recombinase-activatable AAV packaging cassettes for use in the production of AV vectors
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US6251677B1 (en) 1997-08-25 2001-06-26 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
EP1080218A1 (en) 1998-05-27 2001-03-07 University of Florida Method of preparing recombinant adeno-associated virus compositions by using an iodixanol gradient
CA2745131C (en) 1998-05-28 2016-08-09 John A. Chiorini Aav5 vector and uses thereof
JP2002523032A (ja) * 1998-08-18 2002-07-30 リサーチ ディベロップメント ファンデーション 遺伝子の発現の増強および制限方法
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
AU768729B2 (en) 1998-11-05 2004-01-08 Trustees Of The University Of Pennsylvania, The Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
DE69929718T2 (de) * 1998-11-09 2006-11-09 Aventis Pharma S.A. Neues regulationssystem zur kontrolle der expression eines transgens
US6491907B1 (en) 1998-11-10 2002-12-10 The University Of North Carolina At Chapel Hill Recombinant parvovirus vectors and method of making
ES2146552B1 (es) 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
US6387368B1 (en) 1999-02-08 2002-05-14 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
WO2002022175A2 (en) * 2000-09-11 2002-03-21 Musc Foundation For Research Development Method and composition for treating tumors by selective induction of apoptosis
US6835568B2 (en) * 2001-10-30 2004-12-28 Virxsys Corporation Regulated nucleic acid expression system
US7271002B2 (en) 2001-11-09 2007-09-18 United States Of America, Represented By The Secretary, Department Of Health And Human Services Production of adeno-associated virus in insect cells
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
WO2003093293A2 (en) 2002-04-29 2003-11-13 Saint Louis University Peptide antagonists of tgf-beta family members and therapeutic uses thereof
ES2862206T3 (es) 2003-06-19 2021-10-07 Genzyme Corp Viriones de AAV con inmunorreactividad disminuida y sus usos
ES2304069B1 (es) 2003-08-22 2009-08-12 Proyecto De Biomedicina Cima, S.L. Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1).
US6852505B1 (en) * 2003-10-15 2005-02-08 Chau-Ting Yeh Hepatitis
US8242081B2 (en) 2005-12-06 2012-08-14 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
CN101481704A (zh) * 2009-01-21 2009-07-15 中国人民解放军第四军医大学 一种四环素严紧调控的真核表达载体

Also Published As

Publication number Publication date
BR112012010755A2 (pt) 2015-09-22
CN102712933A (zh) 2012-10-03
EP2497830A1 (en) 2012-09-12
CA2780671A1 (en) 2011-05-12
WO2011054994A1 (es) 2011-05-12
US20120225933A1 (en) 2012-09-06
AU2010316996A1 (en) 2012-06-14
JP2014503173A (ja) 2014-02-13
RU2012123145A (ru) 2013-12-10

Similar Documents

Publication Publication Date Title
MX2012005340A (es) Sistemas de expresion regulada.
UA115022C2 (uk) Трансгенна рослина, яка містить нуклеїнову кислоту, що має виділену нуклеотидну послідовність, яка кодує модифіковану інтеїном ксиланазу
NZ612323A (en) Nucleic acid molecules that confer resistance to coleopteran pests
IN2012DN00427A (es)
JP2016528918A5 (es)
WO2012007919A3 (en) Nucleic acid construct for increasing abiotic stress tolerance in plants
WO2013173535A3 (en) Inducible promoter sequences for regulated expression and methods of use
AR097495A1 (es) Constructos para expresar transgenes con el uso de elementos reguladores provenientes de genes ubiquitina 1c de brachypodium
WO2009146015A3 (en) Promoter, promoter control elements, and combinations, and uses thereof
WO2009134027A3 (en) Anti-nucleic acid antibody inducing cell death of cancer cells and composition for preventing or treating cancers comprising the same
BRPI0516039A (pt) moléculas promotoras para o uso em plantas
EA201171449A1 (ru) Обратная генетика с использованием неэндогенных промоторов pol 1
PH12014501554A1 (en) Compositions and methods for the expression of a sequence in a reproductive tissue of a plant
MX356630B (es) Uso del promotor rd29 o fragmentos del mismo para expresión de transgenes inducible por estrés en algodón.
IN2014DN10111A (es)
BRPI0515263A (pt) moléculas promotoras para o uso em plantas
BRPI0515302A (pt) moléculas promotoras para uso em plantas
WO2009060402A3 (en) Plant promoters of the xvsap1 gene
NZ608144A (en) Sugarcane bacilliform viral (scbv) enhancer and its use in plant functional genomics
WO2010146043A3 (en) System for the heterologous expression of a viral protein in a ciliate host cell
AR109791A1 (es) Promotor vegetal para la expresión de transgenes
WO2007077398A3 (fr) Promoteurs de genes pouvant etre utilises chez les plantes
WO2009124285A3 (en) Double-inducible gene activation system and its applications
PH12017500698A1 (en) Synthetic bi-directional plant promoter
UA109141C2 (uk) Трансгенна рослина зі збільшеним рівнем рослинного крохмалю

Legal Events

Date Code Title Description
FA Abandonment or withdrawal